JPMorgan Chase & Co. Acquires 123,271 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

JPMorgan Chase & Co. grew its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 28.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 553,161 shares of the medical instruments supplier's stock after purchasing an additional 123,271 shares during the period. JPMorgan Chase & Co. owned approximately 1.36% of AngioDynamics worth $4,304,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its holdings in shares of AngioDynamics by 110.4% during the third quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier's stock valued at $1,240,000 after purchasing an additional 83,622 shares in the last quarter. State Street Corp boosted its position in shares of AngioDynamics by 2.7% during the third quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier's stock valued at $6,305,000 after buying an additional 21,218 shares during the last quarter. First Eagle Investment Management LLC purchased a new stake in shares of AngioDynamics during the second quarter valued at $1,321,000. Systematic Financial Management LP boosted its position in shares of AngioDynamics by 8.4% during the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier's stock valued at $12,763,000 after buying an additional 162,972 shares during the last quarter. Finally, CWM LLC boosted its position in shares of AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier's stock valued at $76,000 after buying an additional 8,832 shares during the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

AngioDynamics Trading Down 2.7 %

ANGO stock traded down $0.34 during trading on Friday, reaching $12.43. The stock had a trading volume of 551,568 shares, compared to its average volume of 593,298. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $13.13. The stock's 50 day moving average is $8.75 and its two-hundred day moving average is $7.65. The firm has a market cap of $503.04 million, a PE ratio of -2.21 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.90 million for the quarter, compared to the consensus estimate of $70.93 million. During the same quarter in the prior year, the company earned ($0.05) earnings per share. AngioDynamics's revenue was down .1% on a year-over-year basis. On average, research analysts anticipate that AngioDynamics, Inc. will post -0.36 EPS for the current year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares of the company's stock, valued at $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ANGO. HC Wainwright increased their price objective on AngioDynamics from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Canaccord Genuity Group dropped their price objective on AngioDynamics from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, October 4th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.